Login to Your Account

New Indication Broad, Ambiguous

Novel Indication Trips up Humira, Snags Cimzia at Arthritis Adcom

By Mari Serebrov
Washington Editor

Wednesday, July 24, 2013

The FDA's Arthritis Advisory Committee struggled to flip its mind around a broad novel indication of axial spondyloarthritis (axSpA) Tuesday, voting 7-6, with one abstention, to recommend FDA approval of UCB SA's Cimzia to treat active axSpA.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription